Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | HTR1A | P08908 | 10/20 | 0.39 |
| ▸ | DRD2 | P14416 | 10/20 | 0.39 |
| ▸ | HTR2A | P28223 | 10/20 | 0.39 |
| ▸ | DRD3 | P35462 | 7/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769518 | 0.89 | NPC1 (0.39) | RAB9ANPC1HTR1ADRD2HTR2A | |
| SCHEMBL7606898 | 0.75 | MEN1 (0.34) | RAB9A | |
| SCHEMBL4772813 | 0.73 | NPC1 (0.44) | RAB9ANPC1HTR1ADRD2HTR2A | |
| SCHEMBL4792038 | 0.71 | NPC1 (0.61) | RAB9ANPC1WNT1DYRK1ASMYD3 | |
| SCHEMBL2086888 | 0.66 | ALDH1A1 (0.63) | KCNH2 | |
| SCHEMBL4774485 | 0.66 | TP53 (0.40) | DYRK1A | |
| SCHEMBL2156713 | 0.66 | RAB9A (0.58) | RAB9ANPC1SMYD3L3MBTL1 | |
| SCHEMBL5377839 | 0.66 | KDM4E (0.31) | — | |
| SCHEMBL18705837 | 0.65 | HPGD (0.50) | RAB9ANPC1L3MBTL1 | |
| SCHEMBL16050557 | 0.65 | HPGD (0.55) | RAB9ANPC1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | claimed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | claimed |
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | RAB9A 440/4885NPC1 1992/4885HTR1A 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.